OptaBlate, which is the company’s first interventional oncology technology, is said to optimise every aspect of the procedure, starting from set-up to ablation
American medical technology company Stryker has received the US Food and Drug Administration (FDA) 510(k) clearance for its OptaBlate bone tumour ablation system, designed for patients having metastatic tumours.
With the inclusion of OptaBlate technology, Stryker’s interventional spine (IVS) portfolio now offers a full range of therapeutic options for metastatic vertebral body fractures.
The bone tumour ablation, which is based on the firm’s patented microinfusion technology, is said to expand its capabilities in vertebral augmentation and radiofrequency ablation.
According to the firm, OptaBlate is its first interventional oncology device. The system is designed to improve every step of the procedure, from preparation to ablation.
The medical technology firm said that OptaBlate has four probes which enable physicians to modify their procedure and cut ablation time by three minutes.
Stryker claimed that the microinfusion technology keeps the zone hydrated, reduces impedance errors and prevents charring.
The OptaBlate uses a bipedicular approach for the simultaneous treatment of two vertebral body levels.
Stryker interventional spine business vice president and general manager Greg Siller said: “Our commitment to our customers and understanding their needs has never been stronger.
“The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs.
“OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning.”
In July 2021, the company secured FDA approval for its InSpace balloon implant, which is designed for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs).